Jeong K, Kim M, Kim YH, et al. - Researchers undertook this randomized, double‐blind, placebo‐controlled study to assess the curative impact as well as the safety of tyndallized Lactobacillus rhamnosus (IDCC 3201, isolated from the feces of a Korean breastfed‐infant, repeated heat treated and incubated, RHT3201) among children suffering from atopic dermatitis (AD). Children (aged 1 to 12 years) with moderate AD were administered RHT3201 at a dose of 1.0 x 1010 CPU/day or placebo for 12 weeks. SCOring of AD (SCORAD) scores, allergic inflammatory markers, and safety parameters were assessed. Relative to baseline, a significantly greater change of SCORAD total score was evident at 12 week in RHT3201 group (‐13.89 ± 10.05) vs the control group (‐8.37 ± 9.95). Overall, a therapeutic effect of RHT3201, given orally, on AD was evident in this patient population, and the impacts were shown to be correlated, in part, with reduction of eosinophil cationic protein and IL‐31, and experts noted that the effect was more remarkable in subgroup analysis.